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ABSTRACT
Background: Phase Three of the International Study of
Asthma and Allergies in Childhood (ISAAC) measured the
global prevalence and severity of asthma symptoms in
children.
Methods: A cross-sectional questionnaire survey of
798 685 children aged 13–14 years from 233 centres in
97 countries, and 388 811 children aged 6–7 years from
144 centres in 61 countries, was conducted between
2000 and 2003 in .90% of the centres.
Results: The prevalence of wheeze in the past 12 months
(current wheeze) ranged from 0.8% in Tibet (China) to
32.6% in Wellington (New Zealand) in the 13–14 year olds,
and from 2.4% in Jodhpur (India) to 37.6% in Costa Rica in
the 6–7 year olds. The prevalence of symptoms of severe
asthma, defined as >4 attacks of wheeze or >1 night per
week sleep disturbance from wheeze or wheeze affecting
speech in the past 12 months, ranged from 0.1% in Pune
(India) to 16% in Costa Rica in the 13–14 year olds and from
0% to 20.3% in the same two centres, respectively, in the
6–7 year olds. Ecological economic analyses revealed a
significant trend towards a higher prevalence of current
wheeze in centres in higher income countries in both age
groups, but this trend was reversed for the prevalence of
severe symptoms among current wheezers, especially in
the older age group.
Conclusion: Wide variations exist in the symptom
prevalence of childhood asthma worldwide. Although
asthma symptoms tend to be more prevalent in more
affluent countries, they appear to be more severe in less
affluent countries.
Asthma is one of the most common non-commu-
nicable diseases in children. The increase in asthma
prevalence in developed countries seen at the end
of the last century has raised concern for the
considerable burden of this disease on society as
well as individuals. Until a decade ago, there were
few data on asthma prevalence from developing
countries. Recently, the International Study of
Asthma and Allergies in Childhood (ISAAC), using
a simple and inexpensive standardised methodol-
ogy, has provided valuable data on the prevalence
of the symptoms of childhood asthma, rhinocon-
junctivitis and eczema for international compar-
ison from countries with different socio-economic
backgrounds.1–3
Phase One of this global study was conducted
over the early to mid 1990s and involved .700 000
schoolchildren aged 6–7 and 13–14 years from
156 centres in 56 countries. It revealed marked
geographic variations in the prevalence of asthma
symptoms, even within genetically similar
groups.2 3 These findings strongly suggested that
environmental factors were likely to be responsible
for the observed variations. Phase Three of ISAAC,
using the same methodology as Phase One and
conducted around the turn of the century, was
undertaken to examine time trends in the pre-
valence of symptoms of asthma and related
disorders and to provide more comprehensive
information on how the prevalence of these
symptoms varies across the world. These time
trends data were derived from centres which
participated in both phases and have been pub-
lished elsewhere.4 5 This current paper gives a more
comprehensive description of the worldwide pre-
valence of asthma symptoms, including those
which indicate clinically more severe disease, by
presenting data not only from centres included in
the time trends analysis, but also data from 128
new centres which participated solely in Phase
Three. The majority of these new centres were
from developing countries in Latin America,
Eastern Europe and Africa which have few, if
any, epidemiological data on asthma
(Supplementary table S1). With the diverse socio-
economic backgrounds of the participating centres,
these data are useful not only as a basis for
studying the burden of childhood asthma world-
wide, but also for exploring the impact of
economic development on the prevalence and
severity of asthma symptoms.
METHODS
Study design and questionnaires
Details of the Phase Three study protocol have
been published elsewhere.6 This multicountry
cross-sectional survey involved schoolchildren of
two age groups, 6–7 years and 13–14 years. The
study instruments were comprised of a standar-
dised written questionnaire on symptoms of
asthma, rhinoconjunctivitis and eczema, and a
video questionnaire showing five different scenes
of asthma symptoms.7 Both questionnaires were
self-completed by adolescents in the 13–14 year age
group whereas the written questionnaire only was
completed by parents of children in the 6–7 year
age group. The results for the symptoms of
rhinoconjunctivitis and eczema will be reported
in separate publications.
In this study, we estimated the prevalence of
asthma symptoms based on the responses to (1) the
written questionnaire on (a) wheeze in the past
12 months (current wheeze) and (b) frequent or
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severe episodes of wheeze in the past 12 months (symptoms
of severe asthma), and (2) symptoms in the past 12 months
reported from the video questionnaire which showed a young
person wheezing at rest. Symptoms of severe asthma are
defined as those with current wheeze who, according to the
written questionnaire, in the past 12 months, have had >4
attacks of wheeze, or >1 night per week sleep disturbance
from wheeze, or wheeze affecting speech. This definition is
based on previous ISAAC analyses that showed a combina-
tion of these features of more severe wheezing episodes
correlated more closely with asthma mortality and hospital
admissions than current wheeze alone.8 Reported ‘‘asthma
ever’’ was defined from the question ‘‘Have you (Has your
child) ever had asthma?’’.
The written questionnaire was translated from English,
according to the ISAAC Phase Three protocol, 6 into one local
language in 191 centres (80.3%), and into more than one in 15
centres (6.3%). If any back-translated questions were inaccu-
rate, those questions were not used in the analyses. A total of 54
different languages were used (Supplementary table S1). English
and Spanish were the most common languages (21.0% and
20.2% of centres respectively).
Data analysis
We assessed each centre’s adherence to the ISAAC protocol and
excluded any with serious discrepancies; minor deviations are
noted with footnotes in Supplementary table S1. Response rate
was calculated by the number of participants divided by the
sum of the total number of eligible children from the
participating schools in that centre. Symptom prevalence values
in each centre were calculated by dividing the number of
positive responses to each question by the number of completed
questionnaires for the written and video questionnaires
separately. Thus, any apparent inconsistencies between
responses to the stem and branch questions were accepted
and not recoded. To assess the proportion of children with more
severe manifestations of the disease amongst those with asthma
symptoms, the number of respondents with severe wheeze was
divided by the number of current wheezers derived from the
written questionnaire. The kappa statistic was used to examine
the relationships between the written and video questionnaire
in the 13–14 year age group. An ecological economic analysis
was performed to examine the effect of economic development
on the prevalence of asthma symptoms. This analysis used a
generalised linear mixed model with a logit link and the centre
as a random effect to examine the association between country-
level gross national income (GNI) and the centre-level symptom
data. The GNI data were categorised into low, middle and high
based on World Bank cut-off values for 2001.9 The regional
analyses were based on the standard ISAAC regions which are
broadly the same as the regions defined by the World Health
Organization, but we also performed analyses specifically for
English language countries (Australia, Canada, Isle of Man, New
Zealand and the UK for 6–7 year olds, and Australia, Canada,
Channel Islands, Isle of Man, New Zealand, Republic of Ireland,
the UK and the USA for the 13–14 year olds). All analyses were
carried out using SAS version 9.1. A p value of ,0.05 was
considered significant.
RESULTS
Altogether 407 data sets from both age groups were received and
the data and methodology checks were completed. Of these, 30
were excluded due to low response rates (16 data sets), ,1000Ta
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participants (12) or an inability to calculate a response rate (2).
The remaining 377 data sets comprised 1 187 496 school-
children from 237 centres in 98 countries, of which 128 centres
(689 413 participants) in 64 countries (34 new countries) had
not undertaken ISAAC Phase Three time trends studies.
The 13–14 year age group
There were 798 685 participants from 233 centres in 97
countries. The overall response rate was 88.1%
(Supplementary table S1). The global average for current
wheeze based on the written questionnaire was 14.1%, ranging
from 5.1% in Northern and Eastern Europe to 22% in Oceania
(table 1). Thirty-five centres (15%) had a prevalence of current
wheeze >20% and these were mostly from the English language
countries and Latin America. Twenty-two centres (9.4%) had a
prevalence of ,5% and they were mostly in the Indian
subcontinent, Asia-Pacific, Eastern Mediterranean, and
Northern and Eastern Europe (fig 1).
Globally, 6.9% of adolescents had symptoms of severe
asthma, ranging from 3.8% in Asia-Pacific and Northern and
Eastern Europe to 11.3% in North America (table 1). Similar to
current wheeze, centres with the highest prevalence of severe
asthma symptoms (>7.5%) were mostly found in the English
language countries and Latin America, although these also
included many centres in Africa. Centres with the lowest
prevalence (,2.5%) were again located mainly in the Indian
subcontinent, Northern and Eastern Europe, Asia-Pacific and
the Eastern Mediterranean (fig 2 and Supplementary table 2).
However, a different pattern was observed in the proportion of
current wheezers with symptoms of severe asthma. Africa (51%),
the Indian subcontinent (48.2%) and the Eastern Mediterranean
(47.2%) were ranked higher than English language countries
(46%) and Latin America (38.3%) (Supplementary fig S1).
Globally, 20% of current wheezers with symptoms of severe
asthma did not report ‘‘asthma ever’’. This was more commonly
seen in the Eastern Mediterranean (28.8%), Africa (28.5%), the
Indian subcontinent (24.5%) and Northern and Eastern Europe
(23.4%) than in Asia-Pacific (20%), Latin America (18.9%), English
language countries (17.5%) or Western Europe (15.2%) (table 1
and Supplementary fig S2).
A total of 526 103 adolescents from 136 centres in 60
countries completed the video questionnaire. In general, the
symptom prevalence rates for current wheeze based on the
video questionnaire were lower than those derived from the
written questionnaire, and there was a fair agreement between
these measures (kappa = 0.39, 95% CI 0.38 to 0.39) (table 1 and
Supplementary table S2).
The 6–7 year age group
There were 388 811 participants from 144 centres in 61
countries. The overall response rate was 84.5%
(Supplementary table S1). The mean global prevalence for
current wheeze was 11.5%, ranging from 6.8% in the Indian
subcontinent to 21.7% in Oceania (table 2). Twenty-one centres
Figure 1 Prevalence of current wheeze according to the written questionnaire in the 13–14 year age group. See text for definition of current wheeze.
The symbols indicate prevalence values of ,5% (blue square), 5 to ,10% (green circle), 10 to ,20% (yellow diamond) and .20% (red star).
Asthma
478 Thorax 2009;64:476–483. doi:10.1136/thx.2008.106609
 group.bmj.com on February 13, 2010 - Published by thorax.bmj.comDownloaded from 
(14.6%) had a prevalence of current wheeze >20%, and all but
two were in English language countries or Latin America.
Seventeen centres (11.8%) had a prevalence of ,5%, and these
were mostly from the Indian subcontinent, Asia-Pacific and
Northern and Eastern Europe (fig 3 and Supplementary table S3).
There were 4.9% of children worldwide with symptoms of
severe asthma, ranging from 3.2% in Asia-Pacific and Northern
and Eastern Europe to 9.5% in Oceania (table 2). Centres with
high prevalence (>7.5%) were mostly found in Latin America
and English language countries, whereas most of the low
prevalence (,2.5%) centres were from the Indian subcontinent,
Asia-Pacific and Northern and Eastern Europe (fig 4). However,
centres with a high proportion of current wheezers with
symptoms of severe asthma (>50%) were mostly seen in the
Indian subcontinent, Eastern Mediterranean, Africa and Latin
America. Those with a low proportion (,30%) were mostly
from Asia-Pacific and Northern and Eastern Europe
(Supplementary fig S3). Globally, 16.5% of current wheezers
with severe asthma symptoms had never received a diagnosis of
asthma. Undiagnosed asthma amongst these subjects was
highest in Africa (40.2%) and lowest in English language
countries (5.8%) (table 2 and Supplementary fig S4).
Associations with GNI
Centres in lower income countries tended to have lower
prevalence of current wheeze based on the written questionnaire
(odds ratios (OR) for low vs high income 0.49 (95% CI 0.37 to
0.66) and 0.55 (0.42 to 0.72) for the younger and older age groups,
respectively) as well as reported ‘‘asthma ever’’ (OR 0.29 (0.21 to
0.41) and 0.35 (0.27 to 0.46) for the younger and older age groups,
respectively) in both age groups. While the same trend was seen
with symptoms of severe asthma in the younger age group (OR
0.61 (0.42 to 0.89)), this failed to reach statistical significance in
the older age group (OR 0.77 (0.58 to 1.02)). However, the trend
with GNI was reversed for the prevalence of symptoms of severe
asthma among those with current wheeze, although this was
only statistically significant in the older age group (OR 1.46 (1.21
to 1.75); OR 1.24 (0.94 to 1.63) for the younger age group).
Centres in lower income countries also tended to have a higher
proportion of their current wheezers with symptoms of severe
asthma who had no reported ‘‘asthma ever’’ (OR 2.1 (1.48 to 2.99)
and OR 1.90 (1.53 to 2.35) for the younger and older age groups,
respectively).
DISCUSSION
The ISAAC Phase Three study, with its much greater number of
schoolchildren, participating centres and countries than those of
Phase One, has again shown that striking variations in the
prevalence of asthma symptoms exist between different
geographic areas and populations. Generally, the differences in
prevalence between countries were more marked than those
within individual countries. There were 13-fold and 9-fold
Figure 2 Prevalence of symptoms of severe asthma according to the written questionnaire in the 13–14 year age group. See text for definition of
symptoms of severe asthma. The symbols indicate prevalence values of ,2.5% (blue square), 2.5 to ,5% (green circle), 5 to ,7.5% (yellow diamond)
and .7.5% (red star).
Asthma
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Table 2 Prevalence of asthma symptoms in the 6–7 year age group by region
Region (no of centres) Year No*
Current
wheeze
Asthma
ever
Symptoms of severe
asthma (total
participants
denominator)
Symptoms of severe asthma{
(current wheeze
denominator)
Symptoms of severe
asthma without asthma
ever{ (current wheeze
denominator)
No (%) No (%) No (%) No (%) No (%)
Africa (2) 2003 5876 590 (10.0) 202 (3.4) 532 (9.1) 308 (52.2) 237 (40.2)
Asia-Pacific (18) 2000 60052 5723 (9.5) 6572 (10.9) 1893 (3.2) 1639 (28.6) 677 (11.8)
Eastern Mediterranean (13) 2000 40573 3824 (9.4) 2823 (7.0) 1920 (4.7) 1690 (44.2) 847 (22.1)
Indian subcontinent (16) 2002 50106 3395 (6.8) 2271 (4.5) 1766 (3.5) 1430 (42.1) 669 (19.7)
Latin America (35) 2002 93851 16266 (17.3) 10495 (11.2) 7289 (7.8) 6683 (41.1) 3071 (18.9)
North America (2) 2002 4014 767 (19.1) 803 (20.0) 283 (7.1) 282 (36.8) 51 (6.6)
Northern and Eastern
Europe (21)
2001 42583 3717 (8.7) 1719 (4.0) 1350 (3.2) 1270 (34.2) 719 (19.3)
Oceania (6) 2002 13888 3020 (21.7) 4053 (29.2) 1318 (9.5) 1297 (42.9) 161 (5.3)
Western Europe (31) 2002 77868 7497 (9.6) 7536 (9.7) 2826 (3.6) 2666 (35.6) 945 (12.6)
English language
centres{ (8)
2002 18035 3784 (21.0) 4999 (27.7) 1674 (9.3) 1648 (43.6) 218 (5.8)
Global total (144) 2001 388811 44799 (11.5) 36474 (9.4) 19177 (4.9) 17265 (38.5) 7377 (16.5)
Symptoms of severe asthma: respondents with current wheeze who had>4 attacks of wheeze in the last year or had>1 nights per week sleep disturbance from wheeze in the last
year or had wheeze affecting speech in the last year.
*Number of children. {The data presented are restricted to respondents who answered ‘‘yes’’ to the question about current wheeze. {Centres in Australia, Canada, Isle of Man, New
Zealand and the UK.
Figure 3 Prevalence of current wheeze in the 6–7 year age group. See text for definition of current wheeze. The symbols indicate prevalence values of
,5% (blue square), 5 to ,10% (green circle), 10 to ,20% (yellow diamond) and .20% (red star).
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differences between countries with the highest (Costa Rica
37.6% and Isle of Man 31.2%) and lowest (Indonesia 2.8% and
Albania 3.4%) prevalence rates of 12-month wheeze based on
the written questionnaire in the 6–7 year and 13–14 year age
groups, respectively. The intercentre variations were even
bigger, ranging from from 2.4% in Jodhpur (India) to 37.6% in
Costa Rica in the 6–7 year age group and from 0.8% in Tibet
(China) to 32.6% in Wellington (New Zealand) in the 13–14
year age group. The intercountry variations are also large for the
prevalence of symptoms of severe asthma, ranging from 1.1% in
Indonesia to 20.3% in Costa Rica in the 6–7 year olds, and from
1.1% in Albania to 16% in Costa Rica in the 13–14 year olds. At
the centre level, the values ranged from 0% in Pune (India) to
20.3% in Costa Rica in the older age group and from 0.1% to
16% in the two respective centres in the younger age group
(Supplementary tables S2, S3).
While the clinical significance of having only one wheezing
episode in a year is questionable, the occurrence of frequent,
sleep-disturbing or speech-limiting attacks is widely accepted as
clinically important. The latter two symptoms, in particular, are
highly specific for bronchial hyper-responsiveness to methacho-
line.7 Furthermore, the prevalence of symptoms of severe
asthma, defined in the same way as the current study, has
been shown to correlate more strongly than that of current
wheeze with national asthma hospitalisation and mortality
rates in both age groups.8 Severe or frequent symptoms are also
less likely to go unnoticed by subjects who have no family
history of asthma and come from deprived family back-
grounds,10 such as those in the developing countries. The
prevalence rates of symptoms of severe asthma can therefore be
justifiably used as surrogates of disease burden, especially in
areas where data on healthcare utilisation and mortality are
unavailable. The standardised way in which the study was
conducted, as well as its high response and participation rates,
also makes these data useful for comparisons of asthma burden
between different populations and time points.
The international patterns of severe wheeze are in accord
with those seen for current wheeze in both age groups—that is,
the highest ranked centres were mostly from the English
language countries and Latin America, and the lowest ranked
ones were mainly found in the Indian subcontinent, Asia-
Pacific, the Eastern Mediterranean, and Northern and Eastern
Europe. Africa, however, had proportionally more centres with
a high prevalence of severe asthma symptoms than for current
wheeze. The proportion of current wheezers with severe
asthma symptoms was higher in Africa, the Indian subconti-
nent and the Eastern Mediterranean than in the English
language countries for both age groups. This suggests that the
disease may be clinically more severe in these less affluent
countries than the more affluent English language countries,
although the latter have amongst the highest symptom
prevalence of asthma worldwide. Ecological economic analyses
also revealed that although the high-income centres tended to
have a higher prevalence of current wheeze, a reverse trend was
Figure 4 Prevalence of symptoms of severe asthma in the 6–7 year age group. See text for definition of symptoms of severe asthma. The symbols
indicate prevalence values of ,2.5% (blue square), 2.5 to ,5% (green circle), 5 to ,7.5% (yellow diamond) and .7.5% (red star).
Asthma
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found in the prevalence of symptoms of severe asthma among
current wheezers. There may be several reasons underlying this
observation. First, asthma care is likely to be poorer in these
developing countries, although a recent epidemiological survey
showed that suboptimal asthma management was a global
phenomenon.11–13 Secondly, there may be less awareness of
wheeze being a symptom of asthma, even in those with
frequent wheezing, similar to the situation amongst ethnic
minorities in developed countries.14 This notion is further
supported by the finding that undiagnosed asthma among
those current wheezers with severe asthma symptoms was
most commonly seen in these lower income countries
(Supplementary figs S2, S4). Children with undiagnosed
frequent symptoms are also more likely to receive inadequate
care for their asthma and may fall into a vicious downward
spiral of asthma control.14 Thirdly, differences in the levels of
environmental exposure, including air pollutants and infective
agents, may also contribute to the greater severity observed in
these countries. These reasons may also explain the observed time
trends of asthma prevalence—that is, prevalence has decreased in
previously high prevalence countries, such as the affluent English
language countries, but increased in the less affluent developing
countries where prevalence was previously low.5
ISAAC Phase One revealed high prevalences of reported
asthma symptoms in English language countries and Latin
America, a higher prevalence in Western Europe than Eastern
Europe with a clear Northwest–Southeast gradient, and
relatively low prevalences in Africa and Asia.2 3 The current
Phase Three study, with the addition of 128 new centres,
confirmed that high prevalence centres were mostly in English
language countries and Latin America, as well as confirming the
Northwest–Southeast gradient seen in Europe. However, the
additional new centres in Africa showed that the prevalence of
asthma symptoms in this continent, especially those of severe
disease, were one of the highest in the world. While Asia-Pacific
and the Indian subcontinent still had many low prevalence
centres, new centres such as Ho Chi Minh City (Vietnam) and
Sri Lanka were among the highest. Other new centres of interest
include Tibet (China), which had the lowest prevalence of
current wheeze in the adolescents, and the additional centres in
Mexico, which had low prevalence rates in contrast to the
generally high rates seen in Latin America. Further studies on
these centres of extreme prevalence rates, especially among
those of similar ethnic background, may help define the
causative factors for asthma. A previous ISAAC Phase Two
study on 9- to 10-year-old Chinese schoolchildren in Hong Kong
and two cities in mainland China (Guangzhou and Beijing) has
shown that the higher prevalence of asthma symptoms in Hong
Kong could be explained by differences in environmental factors
and diet.15
ISAAC phase three has provided the most comprehensive
estimate of the worldwide symptom prevalence of asthma to
date. This data set comprises centres of different levels of
economic development from every continent, including many
from developing countries in Africa, Eastern Europe and Latin
America where asthma prevalence and severity data, until now,
were scant or non-existent. While English language countries
and Latin America may have the highest prevalence of asthma,
the disease appears to be less often recognised and more severe
in Africa, the Indian subcontinent and the Eastern
Mediterranean. This global map of asthma is invaluable not
only for public health planning, but also for generating
hypotheses in explaining the aetiological factors for this
common disorder.
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of Tonga); F Forastiere (Department of Epidemiology, localHealth Authority, Rome,
Italy); L Garcı´a-Marcos (Instituto de Salud Respiratoria, Universidad de Murcia, Spain);
U Keil* (Institut fu¨r Epidemiologie und Sozialmedizin, Universita¨t Mu¨nster, Germany);
C K W Lai* (Department of Medicine and Therapeutics, The Chinese University of Hong
Kong, Hong Kong); J Mallol* (Department of Respiratory Medicine, University of
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Institute, Melbourne, Australia); J Shah* (Jaslok Hospital & Research Centre, Mumbai,
India); A W Stewart (Population Health, Faculty of Medical and Health Sciences, The
University of Auckland, New Zealand); D Strachan (Department of Public Health
Sciences, St Georges, University of London, UK); E von Mutius (Dr von Haunerschen
Kinderklinik de Universita¨t Mu¨nchen, Germany); S K Weiland (Department of
Epidemiology, University of Ulm, Germany); G Weinmayr (Institute of Epidemiology,
University of Ulm, Germany); H Williams (Centre for Evidence Based Dermatology,
Queen’s Medical Centre, University Hospital, Nottingham, UK); G Wong (Department
of Paediatrics, Prince of Wales Hospital, Hong Kong, SAR China).
*Regional Coordinators
ISAAC International Data Centre: M I Asher, T O Clayton, P Ellwood, E A Mitchell,
Department of Paediatrics: Child and Youth Health; and A W Stewart, School of
Population Health, Faculty of Medical and Health Sciences, The University of Auckland,
New Zealand.
ISAAC Phase Three National Coordinators not identified in Supplementary table S1:
Canada, Professor Malcolm Sears; Channel Islands, Professor Ross Anderson; Chile,
Dr Viviana Aguirre; Columbia (interim), Professor Javier Mallol; Croatia, Professor
Vladimir Ahel; Greece, Associate Professor Christina Gratziou; Hong Kong,
Dr Christopher Lai; India, Dr Jayant Shah; Indonesia, Professor Karnen
Baratawidjaja; Isle of Man, Professor Ross Anderson; Japan, Professor Sankei
Nishima; Kingdom of Tonga, Dr Toakase Fakakovi; The Netherlands, Dr Roy Otten;
Nouvelle Caledonie, Dr Sylvie Barny; Polynesie Francaise, Dr Rene´ Chansin; Republic
of Ireland, Dr Patrick Manning; Republique Democratique du Congo, Dr Etienne
Bahati; Russia, Professor Rakhim M Khaitov; Samoa, Dr Nuualofa Tuuau-Potoi;
Singapore, Professor Beewah Lee; Sudan, Dr Asma El Sony; Sweden, Dr Lennart
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An unusual case of dyspnoea
CLINICAL PRESENTATION
A 66-year-old woman presented with progressive exertional
dyspnoea, productive cough and dysphonia, particularly when
singing; she also experienced a dry obstructed nose, sore mouth
and mild dysphagia. She had previously been diagnosed with
autoimmune disease affecting her eyes, nasal passages, oro-
pharynx and oesophagus, for which she had received treatment
with prednisolone and cyclophosphamide. Immunosuppression
continued with azathioprine. She also suffered from aortic
stenosis and hypothyroidism, which was treated with levothyr-
oxine. No perinatal respiratory difficulties were known and she
had never been intubated. Despite being a non-smoker, she had
had frequent lower respiratory tract infections.
Physical examination showed no additional signs but chest
radiography revealed ill-defined consolidation in the right upper
lobe. Bronchoscopy was performed to exclude mycobacterial
infection and showed an abnormal supraglottic region with a
ring-like narrowing with scarring extending posteriorly from
fused arytenoids through which the true vocal cords could be
seen (fig 1). The laryngeal structures did not collapse with
inspiration andmovement of the true vocal cords was normal. No
associated glottic or subglottic abnormalities were identified.
QUESTION
What is the abnormality at bronchoscopy and what are the
differential diagnoses? What symptoms can arise?
See page 515.
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Figure 1 Appearance of supraglottic region at bronchoscopy.
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